Cencora Inc
DUS:ABG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Cencora Inc (ABG) under the Base Case is 290.63 EUR per share.
Compared with the current market price of 314.5 EUR, the stock appears
Overvalued by 8% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Cencora Does
Cencora is one of the largest drug distributors in the United States and a major service provider to the pharmaceutical supply chain. It buys medicines and medical products from drug makers, stores them, and delivers them to pharmacies, hospitals, doctors’ offices, clinics, and other healthcare providers. It also offers support services such as specialty drug handling, packaging, consulting, and logistics for manufacturers and healthcare customers.
- Headquarters
- United States of America US
- Employees
- 49 000
- IPO date
- May 28, 1996
Cencora has a narrow economic moat
Spreading warehouse and delivery costs across a large volume of medicines helps Cencora serve customers at costs smaller distributors struggle to match. Its ordering and inventory systems also give customers practical reasons to stay, although McKesson and Cardinal Health offer strong alternatives.
Read the full moat analysis
Revenue & Expenses Breakdown
Cencora Inc
Earnings Waterfall
Cencora Inc
What is the Intrinsic Value of one ABG stock?
The intrinsic value for Cencora Inc (ABG) under the Base Case is 290.63 EUR.
Is ABG stock undervalued or overvalued?
Compared with the current market price of 314.5 EUR, the stock appears Overvalued by 8% .
